IL9 and neoplasm: More importantly, 67% of the IL-9 heterozygous and 50% of the IL-9 knockout mice were tumor free as opposed to 40% in the wild type mice group, indicating an anti-tumoral effect of IL-9 deficient mice (Figure 6I).